Ask AI

Modernize Your T2D Management Practice: Practical Strategies for Integrating Next-Generation, Weekly Basal Insulin Therapies

Start Activity
Podcast
Podcast Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: August 20, 2026

Expiration: August 19, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Podcast 3 Post Assessment 4 Evaluation 5 Credit

Listen in as 2 experts discuss the evolving role of weekly insulin therapy in modern type 2 diabetes (T2D) management. They share practical considerations for initiating or switching to these novel agents, including how to accurately convert daily doses, follow titration schedules, and support adherence and patient preferences through shared decision-making. Learn how you can ensure optimized glycemic control and reduced treatment burden in your patients with T2D by integrating weekly insulin therapies in your endocrinology, diabetology, or primary care practice. 

Richard E. Pratley
Richard E. Pratley, MD
Jay H. Shubrook
Jay H. Shubrook, DO, FAAFP, FACOFP
T2D insights on weekly insulin therapy

Pre Assessment

Assess your current knowledge and clinical approach before beginning your podcast.
Begin Your Podcast
1.

How many people with type 2 diabetes (T2D) do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 58-year-old man with T2D has an A1C of 8.1% despite metformin, an SGLT2 inhibitor, and a maximally tolerated GLP-1 receptor agonist. His fasting glucose values are consistently 160-195 mg/dL. He works rotating shifts and frequently misses daily medications. He is willing to begin insulin but is concerned that another daily treatment will be difficult to sustain. He has no history of severe hypoglycemia and can reliably monitor his glucose. Which treatment plan most appropriately incorporates emerging evidence while addressing this patient’s needs?

4.

A 66-year-old man with T2D uses insulin glargine U100, 42 units once daily. His A1C is 8.6%, and continuous glucose monitoring shows fasting glucose ranging from 95-220 mg/dL. He misses approximately 2 basal doses each week while caring for his spouse. He has stage 3 chronic kidney disease and receives intermittent prednisone bursts for chronic obstructive pulmonary disease exacerbations, during which his insulin requirements increase substantially. He asks whether once-weekly basal insulin would simplify treatment. Which recommendation best accounts for the comparative PK/pharmacodynamics (PD) and dosing characteristics of available basal insulins?

5.

A 72-year-old man with T2D is transitioning from once-daily basal insulin to once-weekly insulin icodec. He also receives once-weekly tirzepatide. During education, he says, “Both pens are weekly, so I’ll keep them together and take whichever one I pick up first every Sunday.” Which intervention is most important before he begins the new regimen?

6.

A 54-year-old woman with T2D has an A1C of 9.4% and fasting glucose values of 190-230 mg/dL despite optimized noninsulin therapy. When basal insulin is discussed, she crosses her arms and says, “Insulin means I failed. My mother started insulin and then developed kidney failure.” Which response is most likely to improve engagement and support an informed treatment decision?

Begin Your Podcast